http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-69636012-T3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ef2e9f5ce8630d9b282043b8d060caff
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-498
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-498
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02
filingDate 1996-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2012-01-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08ddf724f2e9dd83116d2e2a8afa6e74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb6de564e0b42ed785cf3e9076731fd8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_929e44b4392e23defa6b76b10a34e83a
publicationDate 2012-01-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber DE-69636012-T3
titleOfInvention USE OF (2-IMIDAZOLIN-2-YL-AMINO) QUINOXALINES FOR THE TREATMENT OF EYEGEN INJURY
abstract A method according to which neuroprotection is conferred upon ocular nerve cells by administration of a drug of formula (I) to the optic nerve and/or retina of a mammal within a period prior to or following an insult to ocular nerve cells but prior to cell death, wherein the 2-imidazolin-2-ylamino group may be in either the 5- or 6-position of the quinoxaline nucleus; x, y and z may be in any of the remaining 5-, 6-, 7- or 8-positions and are selected from hydrogen, halogen, lower alkyl, lower alkoxy or trifluoromethyl; and R is an optional substituent in either the 2-or 3-position of the quinoxaline nucleus and may be hydrogen, lower alkyl or lower alkoxy is disclosed.
priorityDate 1995-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP19515
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCO59952
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP41773
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP26504
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2435
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCA8WGN9
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ20449
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ3UT41
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466558141
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCD4A9L7
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ9VG48
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414161244
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ55EU1
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP04635
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ5U780
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP61872
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ93MW7
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ5HKP6
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP0C0R3
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCA0A3Q1M1X5
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP61871
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP0C0R4

Total number of triples: 49.